CyBio: Tularik GmbH awards contract worth millions for Screen-machine and replicator

10-Jan-2001 - Germany

CyBio AG has sold a further fully-automatic laboratory system, - the CyBiÔ-Screen-machine. The biotech company from Jena has thereby further promoted their strategy of positioning themselves as system provider of technology platforms for the entire pre-clinical phase. Tularik GmbH, an innovative pharmaceutical research firm, could be gained as a new customer. The sales volume of the contract, which was already concluded by the end of 2000, amounts to more than 1 million DM (0.6 million Euro). Delivery and installation of the system will be completed by the end of January. Follow-up contracts are being discussed.

Tularik Inc., founded in San Francisco in 1991 and listed on NASDAQ since December 1999, has expanded its operations into Europe with Tularik GmbH in the Regensburg BioPark. The company is a forerunner in the field of gene control. The goal is to discover and develop medications that can activate or inhibit areas of DNA that are responsible for the development of diseases such as cancer, diabetes or immune system disorders. These new medications are highly effective, because they act specifically where many diseases originate: on the defective development of certain hereditary traits. In order to implement various research projects, Tularik has entered into strategic alliances with leading pharmaceutical firms, such as Knoll AG, Roche Bioscience and Japan Tobacco.

Tularik is expecting the CyBiTM-Screen-machine and the replicator for sample preparation to speed up medical active substance searches substantially, allowing the firm to add promising new patents to the more than 120 it has registered so far.

https://www.chemeurope.com/en/news/673/cybio-tularik-gmbh-awards-contract-worth-millions-for-screen-machine-and-replicator.html